Regis Resources trades higher with gold flat ahead of ASX open

Regis Resources trades higher with gold flat ahead of ASX open

June 16, 2026

SYDNEY, June 17, 2026, 07:01 AEST

  • Regis Resources finished Tuesday at A$6.69, gaining 0.9%. That came after a 13.3% surge on Monday.
  • Gold stayed firm with oil prices down, easing some worries about more rate hikes. That supported ASX-listed gold stocks.
  • Investors continue to weigh the Regis all-share offer for Vault Minerals, which would form a bigger Australian gold miner.

Regis Resources shares move into Wednesday’s Australian trade after bouncing hard over two sessions. Firmer gold prices and a steadier ASX have brought buyers into local gold miners.

The stock finished at A$6.69 on Tuesday, adding 0.9%, after jumping 13.3% Monday. That’s a 14% rise across two days, clawing back some losses after last month’s proposed merger with Vault Minerals. Shares next trade when the Australian Securities Exchange opens Wednesday, with normal hours from 9:59 a.m. to 4:00 p.m. Sydney time.

Gold is back in play as the swing factor for the stock. Spot gold moved higher, trading at $4,338.86 an ounce on Tuesday. Prices got a lift from lower bets on a U.S. Federal Reserve rate increase, after an interim U.S.-Iran peace deal weighed on oil. Gold doesn’t generate yield, so when rates go up, it loses luster against cash and bonds.

Slight gains for the Australian market as the S&P/ASX 200 edged up 3.7 points, or 0.04%, finishing Tuesday at 8,917.70. The Reserve Bank of Australia kept the cash rate steady at 4.35%. RBA officials said inflation is still running high and signaled a possible rate hike, saying “including increasing the cash rate target further if required.” Business Recorder

Gold stocks were higher too. Northern Star Resources ended at A$21.30, adding 2.45%, and Evolution Mining closed at A$13.08, up 1.16%. That lifted Regis along with the sector, not just on company news.

Regis is still trading as a deal play. Back in May, Regis and Vault said they planned to merge via a Vault scheme of arrangement, which is a court-led process. Vault holders would get 0.6947 new Regis shares per Vault share. The companies together would have a market cap near A$10.7 billion, with gold production above 700,000 ounces a year, according to their statement.

Jim Beyer, managing director and CEO at Regis, said in the statement the deal will make the group “Australia’s third largest primary ASX-listed gold producer.” Vault CEO Luke Tonkin said the merger lets Vault investors keep a stake but get more size, diversification and strength in the balance sheet.

The market response to the deal was mixed. Regis shares dropped as much as 6.1% after the deal was announced, Reuters said, while Vault’s stock jumped. Investors looked at the pricing and execution risk and questioned if the combined company could grow enough to offset dilution. Ord Minnett called it “a positive step forward,” mentioning the bigger platform and new growth options. Reuters

Risks are still hanging over the Vault deal. Shareholders, the court, and regulators still need to sign off, and a better bid or a move in gold could change things fast. The rates picture also isn’t clear. Deloitte Access Economics partner Stephen Smith said the RBA faces “a very cloudy outlook.” Oxford Economics Australia’s Harry Murphy Cruise flagged inflation risk after the oil shock, saying it “cannot simply be put back in the bottle.” Reuters

Stock Market Today

  • Entropy Neurodynamics Accelerates Psychedelic Medicine Trials Amid FDA Developments
    June 16, 2026, 5:56 PM EDT. Entropy Neurodynamics (ASX:ENP) advances phase II trials for its psilocin-based drug targeting binge eating disorder (BED), a condition with complex mental and behavioral symptoms. CEO Jason Carroll supports the imminent FDA approval of Compass Pathways' psilocybin therapy for treatment-resistant depression, which could establish the first regulated psychedelic treatment in the U.S. Recent regulatory easing promises quicker approvals by reducing previous DEA constraints. Entropy's collaboration with Swinburne University shows safety in initial cohorts, with results expected by July. BED's significant treatment challenges highlight the potential impact of Entropy's innovative therapy. The evolving landscape signals growing momentum for psychedelic medicines addressing mental health disorders.